PRAX Strangle Strategy
PRAX (Praxis Precision Medicines, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX (Praxis Precision Medicines, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $7.33B, a beta of 2.78 versus the broader market, a 52-week range of 35.21-358.76, average daily share volume of 416K, a public-listing history dating back to 2020, approximately 116 full-time employees. These structural characteristics shape how PRAX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.78 indicates PRAX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on PRAX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PRAX snapshot
As of May 14, 2026, spot at $346.70, ATM IV 69.20%, IV rank 4.30%, expected move 19.84%. The strangle on PRAX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on PRAX specifically: PRAX IV at 69.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a PRAX strangle, with a market-implied 1-standard-deviation move of approximately 19.84% (roughly $68.78 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PRAX expiries trade a higher absolute premium for lower per-day decay. Position sizing on PRAX should anchor to the underlying notional of $346.70 per share and to the trader's directional view on PRAX stock.
PRAX strangle setup
The PRAX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PRAX near $346.70, the first option leg uses a $360.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PRAX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PRAX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $360.00 | $20.15 |
| Buy 1 | Put | $330.00 | $21.80 |
PRAX strangle risk and reward
- Net Premium / Debit
- -$4,195.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$4,195.00
- Breakeven(s)
- $288.05, $401.95
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PRAX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PRAX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$28,804.00 |
| $76.67 | -77.9% | +$21,138.38 |
| $153.32 | -55.8% | +$13,472.76 |
| $229.98 | -33.7% | +$5,807.15 |
| $306.63 | -11.6% | -$1,858.47 |
| $383.29 | +10.6% | -$1,865.91 |
| $459.95 | +32.7% | +$5,799.71 |
| $536.60 | +54.8% | +$13,465.33 |
| $613.26 | +76.9% | +$21,130.94 |
| $689.92 | +99.0% | +$28,796.56 |
When traders use strangle on PRAX
Strangles on PRAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRAX chain.
PRAX thesis for this strangle
The market-implied 1-standard-deviation range for PRAX extends from approximately $277.92 on the downside to $415.48 on the upside. A PRAX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PRAX IV rank near 4.30% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PRAX at 69.20%. As a Healthcare name, PRAX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PRAX-specific events.
PRAX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PRAX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PRAX alongside the broader basket even when PRAX-specific fundamentals are unchanged. Always rebuild the position from current PRAX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PRAX?
- A strangle on PRAX is the strangle strategy applied to PRAX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PRAX stock trading near $346.70, the strikes shown on this page are snapped to the nearest listed PRAX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PRAX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PRAX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$4,195.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PRAX strangle?
- The breakeven for the PRAX strangle priced on this page is roughly $288.05 and $401.95 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PRAX market-implied 1-standard-deviation expected move is approximately 19.84%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PRAX?
- Strangles on PRAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRAX chain.
- How does current PRAX implied volatility affect this strangle?
- PRAX ATM IV is at 69.20% with IV rank near 4.30%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.